Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth
HOUSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the second quarter ended June 30, 2026 and provided an operational and business update.
Second Quarter and First Half 2026 Financial Summary
- Total revenues of approximately $1.77 million and $3.07 million for the second quarter 2026 and first half of 2026, respectively, were each up in excess of 150% versus the comparable 2025 periods
- Total 2Q product revenues increased 38% sequentially versus 1Q 2026 with Aurix branded product revenues increasing in excess of 30% sequentially
- Second quarter net operating loss of approximately $167,000 improved by approximately $280,000 compared to the first quarter of 2026
- Amended and restated loan agreement with an interim funding of $675,000 and with $325,000 remaining available under commitments totaling $2 million
Operational and Business Update
- Market continues to respond positively to absolute and relative improvement in Medicare related reimbursement for Aurix and a vastly changed overall reimbursement landscape
- Proposed Medicare PFS and OPPS reimbursement rules issued in July for January 1, 2027 effectiveness, if finalized as proposed, would support stable or increasing Medicare payment amounts for autologous PRP therapies
“Market dynamics continue to support attractive growth opportunities for the Aurix brand and, by extension, Smith+Nephew’s private label offering. We remain two months shy of the one-year anniversary of Smith+Nephew’s market entry and the initial availability of their private label brand as another differentiated autologous therapy and are pleased to report that the arrangement continues to perform positively,” commented David Jorden, Nuo’s Chief Executive and Financial Officer. “We recently confirmed the achievement of a reimbursement fee milestone contained in last year’s distribution agreement and anticipate receiving that payment this quarter”.
“We amended January’s loan agreement in May with additional capital made available via an interim funding and have the company option to increase total borrowings under the agreement on September 30, 2026. The loan remains designed to provide working capital as we invest in growth and move closer to breakeven operations”.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, expectations regarding Medicare reimbursement changes and their impact on demand for Aurix products, future receipt of milestone payments, and movement toward breakeven operations. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
Contact:
David Jorden
djorden@nuot.com
| NUO THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 449,325 | $ | 548,946 | ||||
| Accounts receivable, net | 1,167,571 | 561,667 | ||||||
| Inventory, net | 269,518 | 213,761 | ||||||
| Prepaid expenses and other current assets | 107,021 | 55,509 | ||||||
| Total current assets | 1,993,435 | 1,379,883 | ||||||
| Property and equipment, net | 571,735 | 366,315 | ||||||
| Operating lease right of use assets | 61,120 | 99,464 | ||||||
| Total assets | $ | 2,626,290 | $ | 1,845,662 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 563,100 | $ | 436,083 | ||||
| Accrued expenses | 619,046 | 493,792 | ||||||
| Deferred revenue | 311,765 | 300,000 | ||||||
| Current portion of operating lease liabilities | 60,090 | 76,410 | ||||||
| Total current liabilities | 1,554,001 | 1,306,285 | ||||||
| Deferred revenue – long term | 857,353 | 975,000 | ||||||
| Notes payable | 1,436,250 | 300,000 | ||||||
| Note payable – related party | 314,000 | 200,000 | ||||||
| Non-current portion of operating lease liabilities | - | 20,936 | ||||||
| Total liabilities | 4,161,604 | 2,802,221 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' deficit | ||||||||
| Common stock; $0.0001 par value, 100,000,000 shares authorized, 48,418,524 and 48,179,039 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 4,842 | 4,818 | ||||||
| Additional paid-in capital | 34,128,073 | 33,810,785 | ||||||
| Accumulated deficit | (35,668,229 | ) | (34,772,162 | ) | ||||
| Total stockholders' deficit | (1,535,314 | ) | (956,559 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 2,626,290 | $ | 1,845,662 | ||||
| NUO THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||
| Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | |||||||
| Revenue | ||||||||
| Product sales | $ | 1,691,045 | $ | 625,202 | ||||
| Distribution fee revenue | 77,941 | 75,000 | ||||||
| Total revenue | 1,768,986 | 700,202 | ||||||
| Costs of sales | 598,959 | 159,350 | ||||||
| Gross profit | 1,170,027 | 540,852 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative | 1,336,579 | 1,192,874 | ||||||
| Total operating expenses | 1,336,579 | 1,192,874 | ||||||
| Loss from operations | (166,552 | ) | (652,022 | ) | ||||
| Other income (expense) | ||||||||
| Interest income (expense), net | (114,066 | ) | 1,153 | |||||
| Other income | 3,017 | 1,180 | ||||||
| Total other income (expenses) | (111,049 | ) | 2,333 | |||||
| Net loss | $ | (277,601 | ) | $ | (649,689 | ) | ||
| Loss per common share | ||||||||
| Basic and diluted | $ | (0.01 | ) | $ | (0.01 | ) | ||
| Weighted average common shares outstanding | ||||||||
| Basic and diluted | 48,407,917 | 46,823,111 | ||||||
| NUO THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||
| Six Months ended June 30, 2026 | Six Months ended June 30, 2025 | |||||||
| Revenue | ||||||||
| Product sales | $ | 2,915,219 | $ | 1,109,583 | ||||
| Distribution fee revenue | 155,882 | 75,000 | ||||||
| Total revenue | 3,071,101 | 1,184,583 | ||||||
| Costs of sales | 1,051,347 | 280,371 | ||||||
| Gross profit | 2,019,754 | 904,212 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative | 2,632,772 | 2,301,381 | ||||||
| Total operating expenses | 2,632,772 | 2,301,381 | ||||||
| Loss from operations | (613,018 | ) | (1,397,169 | ) | ||||
| Other income (expense) | ||||||||
| Interest income (expense), net | (289,348 | ) | (442 | ) | ||||
| Other income | 6,299 | 1,794 | ||||||
| Total other income (expenses) | (283,049 | ) | 1,352 | |||||
| Net loss | $ | (896,067 | ) | $ | (1,395,817 | ) | ||
| Loss per common share | ||||||||
| Basic and diluted | $ | (0.02 | ) | $ | (0.03 | ) | ||
| Weighted average common shares outstanding | ||||||||
| Basic and diluted | 48,346,949 | 46,819,632 | ||||||
